Insolution q vd oph

Manufactured by Merck Group

InSolution Q-VD-OPh is a broad-spectrum caspase inhibitor used in cell culture research. It is a cell-permeable quinoline-Val-Asp-CH2-OPh compound that inhibits the activity of multiple caspase enzymes, which are key mediators of apoptosis. The product is intended for research use only and the specific details of its function and intended applications should be referred to in the product documentation.

Automatically generated - may contain errors

Lab products found in correlation

2 protocols using insolution q vd oph

Pharmacological Inhibitors in Cancer Research

Check if the same lab product or an alternative is used in the 5 most similar protocols

Dasatinib, GDC-0941, AZD8055, rapamycin and MLN0128 were obtained from LC Laboratories (Woburn, MA); AKT inhibitor VIII from Chemdea (Ridgewood, NJ). InSolution Q-VD-OPh was from EMD Millipore (Billerica, MA); vincristine, doxycycline, etoposide, daunorubicin, MTX, 6-MP, dexamethasone and araC are from Sigma-Aldrich (St. Louis, MO). Palbociclib was purchased from Selleck Chemicals (Houston, TX).

Vo T.T., Lee J.H., Nguyen D., Lui B., Pandori W., Khaw A., Mallya S., Lu M., Müschen M., Konopleva M, & Fruman D.A. (2017). mTORC1 Inhibition Induces Resistance to Methotrexate and 6-Mercaptopurine in Ph+ and Ph-like B-ALL. Molecular cancer therapeutics, 16(9), 1942-1953.

+ Open protocol

+ Expand

Simvastatin Activation and Small Molecule Modulation

Check if the same lab product or an alternative is used in the 5 most similar protocols

Simvastatin, atorvastatin calcium salt, rosuvastatin calcium salt, and fluvastatin sodium salt were obtained from Cayman Chemical Company. Simvastatin was activated as reported elsewhere (48 (link)). Venetoclax and navitoclax were obtained from Active Biochem. InSolution Q-VD-OPh was obtained from EMD Millipore. NVP-BEZ235 was obtained from LC Laboratories. Doxorubicin, vincristine, mevalonate, squalene, cholesterol, farnesyl pyrophosphate, and geranylgeranyl pyrophosphate were all obtained from Sigma-Aldrich.

Lee J.S., Roberts A., Juarez D., Vo T.T., Bhatt S., Herzog L.O., Mallya S., Bellin R.J., Agarwal S.K., Salem A.H., Xu T., Jia J., Li L., Hanna J.R., Davids M.S., Fleischman A.G., O’Brien S., Lam L.T., Leverson J.D., Letai A., Schatz J.H, & Fruman D.A. (2018). Statins enhance efficacy of venetoclax in blood cancers. Science translational medicine, 10(445), eaaq1240.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!